Skip to main content
. 2020 Nov 27;10:20793. doi: 10.1038/s41598-020-77841-1

Table 1.

Selected baseline characteristics of study population.

Variable Total (N = 1,357,736) Women not diagnosed with seropositive RA (N = 1,351,680) Women diagnosed with seropositive RA (N = 6,056) OR (95% CI) p-value
Mean age, y (SD) 61.4 (8.3) 61.4 (8.3) 60.7 (7.6) 0.99 (0.99–0.99)  < 0.001
Age at menarche, N (%)
Mean (SD) 16.5 (1.8) 16.5 (1.8) 16.5 (1.9) 1.01 (0.99–1.02) 0.332
≤ 15 years 422,281 (31.1) 420,445 (31.1) 1836 (30.3) 1 (ref.) 0.474
16 years 287,920 (21.2) 286,618 (21.2) 1302 (21.5) 1.04 (0.97–1.12)
17 years 269,426 (19.8) 268,189 (19.8) 1237 (20.4) 1.06 (0.98–1.14)
≥ 18 years 378,109 (27.9) 376,428 (27.9) 1681 (27.8) 1.02 (0.96–1.09)
Age at menopause, N (%)
Mean (SD) 50.0 (4.0) 50.0 (4.0) 50.0 (4.0) 1.00 (0.99–1.00) 0.499
< 40 years 23,170 (1.7) 23,064 (1.7) 106 (1.8) 1 (ref.) 0.588
40–44 years 77,503 (5.7) 77,131 (5.7) 372 (6.1) 1.05 (0.85–1.30)
45–49 years 369,193 (27.2) 367,536 (27.2) 1657 (27.4) 0.98 (0.81–1.19)
50–54 years 743,286 (54.7) 740,016 (54.8) 3270 (54.0) 0.96 (0.79–1.17)
≥ 55 years 144,584 (10.7) 143,933 (10.7) 651 (10.8) 0.98 (0.80–1.21)
Reproductive period, N (%)
Mean (SD) 33.6 (4.4) 33.6 (4.4) 33.5 (4.4) 1.00 (0.99–1.00) 0.307
< 30 years 186,341 (13.7) 185,493 (13.7) 848 (14) 1 (ref.) 0.660
30–34 years 567,444 (41.8) 564,895 (41.8) 2549 (42.1) 0.99 (0.91–1.07)
35–39 years 517,205 (38.1) 514,913 (38.1) 2292 (37.9) 0.97 (0.90–1.05)
≥ 40 86,746 (6.4) 86,379 (6.4) 367 (6.1) 0.93 (0.82–1.05)
Parity, N (%)
Nulliparous 33,605 (2.5) 33,429 (2.5) 176 (2.9) 1 (ref.) 0.084
1 child 82,685 (6.1) 82,308 (6.1) 377 (6.2) 0.87 (0.73–1.04)
≥ 2 children 1,241,446 (91.4) 1,235,943 (91.4) 5503 (90.9) 0.85 (0.73–0.98)
Duration of breastfeeding, N (%)
Never 90,070 (6.6) 89,617 (6.6) 453 (7.5) 1 (ref.) 0.026
< 0.5 years 89,470 (6.6) 89,089 (6.6) 381 (6.3) 0.85 (0.74–0.97)
0.5 to < 1 years 237,224 (17.5) 236,135 (17.5) 1089 (18.0) 0.91 (0.82–1.02)
≥ 1 years 940,972 (69.3) 936,839 (69.3) 4133 (68.3) 0.87 (0.79–0.96)
Oral contraceptive use, No. (%)
Never used 1,084,881 (79.9) 1,080,038 (79.9) 4843 (80.0) 1 (ref.) 0.477
< 1 years 123,156 (9.07) 122,584 (9.1) 572 (9.5) 1.04 (0.95–1.14)
≥ 1 years 82,398 (6.07) 82,054 (6.1) 344 (5.7) 0.94 (0.84–1.04)
Unknown 67,301 (4.96) 67,004 (5.0) 297 (4.9) 0.99 (0.88–1.11)
Hormone therapy, N (%)
Never used 1,097,847 (80.9) 1,093,086 (80.9) 4761 (78.6) 1 (ref.)  < 0.001
< 2 years 123,195 (9.1) 122,583 (9.1) 612 (10.1) 1.15 (1.05–1.25)
2 to < 5 years 50,640 (3.7) 50,381 (3.7) 259 (4.3) 1.18 (1.04–1.34)
≥ 5 years 38,797 (2.9) 38,583 (2.9) 214 (3.5) 1.27 (1.11–1.46)
Unknown 47,257 (3.5) 47,047 (3.5) 210 (3.5) 1.03 (0.89–1.18)
Smoking history, N (%)
Never smoker 1,306,285 (96.2) 1,300,499 (96.2) 5786 (95.5) 1 (ref.) 0.024
Former smoker 14,512 (1.1) 14,437 (1.1) 75 (1.2) 1.17 (0.93–1.47)
Current smoker 36,939 (2.7) 36,744 (2.7) 195 (3.2) 1.19 (1.03–1.38)
Alcohol consumption, N (%)
Non 1,186,714 (87.4) 1,181,322 (87.4) 5,392 (89.0) 1 (ref.) 0.001
Mild (< 30 g/day) 163,966 (12.1) 163,328 (12.1) 638 (10.5) 0.86 (0.79–0.93)
Heavy (≥ 30 g/day) 7056 (0.5) 7030 (0.5) 26 (0.4) 0.81 (0.55–1.19)
Regular physical activity 251,179 (18.5) 250,138 (18.5) 1041 (17.2) 0.91 (0.86–0.98) 0.009
Anthropometrics
Body mass index, N (%)
< 18.5 kg/m2 28,840 (2.1) 28,670 (2.1) 170 (2.8) 1.25 (1.07–1.56)  < 0.001
18.5 to < 23 kg/m2 469,107 (34.6) 466,886 (34.5) 2221 (36.7) 1 (ref.)
23 to < 25 kg/m2 360,783 (26.6) 359,175 (26.6) 1608 (26.6) 0.94 (0.88–1.00)
25 to < 30 kg/m2 443,423 (32.7) 441,593 (32.7) 1830 (30.2) 0.87 (0.82–0.93)
≥ 30 kg/m2 55,583 (4.1) 55,356 (4.1) 227 (3.8) 0.86 (0.75–0.99)
Systolic BP (mmHg) 125.6 ± 16.2 125.6 ± 16.2 124.3 ± 15.8 1.00 (0.99–1.00)  < 0.001
Diastolic BP (mmHg) 76.9 ± 10.2 76.9 ± 10.2 76.4 ± 10.1 1.00 (0.99–1.00)  < 0.001
Laboratory findings
Glucose (mg/dL) 99.7 ± 24.2 99.7 ± 24.3 96.9 ± 21.5 0.99 (0.99–1.00)  < 0.001
Cholesterol (mg/dL) 208.3 ± 43.9 208.3 ± 43.8 205.2 ± 52.3 1.00 (1.00–1.00)  < 0.001
Comorbidity
Hypertension, N (%) 574,745 (42.33) 572,398 (42.4) 2347 (38.8) 0.86 (0.82–0.91)  < 0.001
Diabetes mellitus, N (%) 174,870 (12.88) 174,248 (12.9) 622 (10.3) 0.77 (0.71–0.84)  < 0.001
Dyslipidemia, N (%) 462,410 (34.06) 460,547 (34.1) 1,863 (30.8) 0.86 (0.81–0.91)  < 0.001
Cancer, N (%) 36, 317 (2.7) 36,193 (2.7) 124 (2.1) 0.76 (0.64–0.91) 0.002
Income
Q1 (lowest) 309,432 (22.8) 308,044 (22.8) 1388 (22.9) 1 (ref.) 0.873
Q2 252,891 (18.6) 251,759 (18.6) 1132 (18.7) 1.00 (0.92–1.08)
Q3 335,670 (24.7) 334,155 (24.7) 1515 (25.0) 1.01 (0.94–1.08)
Q4 (highest) 459,743 (33.9) 457,722 (33.9) 2021 (33.4) 0.98 (0.92–1.05)

OR odds ratio, 95% CI 95% confidence interval, SD standard deviation, BP blood pressure.